Li, M., Yang, Mh., Liu, Y. et al. Analysis of clinical evaluation of response to treatment of Parkinson’s disease with integrated Chinese and Western medicine therapy., Chin. J. Integr. Med. 21, 17–21 (2015). https://doi.org/10.1007/s11655-014-1760-3
Min Li, Ming-hui Yang, Yi Liu, et al. Analysis of clinical evaluation of response to treatment of Parkinson’s disease with integrated Chinese and Western medicine therapy[J]. Chinese Journal of Integrative Medicine, 2015,21(1):17-21.
Li, M., Yang, Mh., Liu, Y. et al. Analysis of clinical evaluation of response to treatment of Parkinson’s disease with integrated Chinese and Western medicine therapy., Chin. J. Integr. Med. 21, 17–21 (2015). https://doi.org/10.1007/s11655-014-1760-3DOI:
Min Li, Ming-hui Yang, Yi Liu, et al. Analysis of clinical evaluation of response to treatment of Parkinson’s disease with integrated Chinese and Western medicine therapy[J]. Chinese Journal of Integrative Medicine, 2015,21(1):17-21. DOI: 10.1007/s11655-014-1760-3.
Analysis of clinical evaluation of response to treatment of Parkinson’s disease with integrated Chinese and Western medicine therapy
摘要
To analyze the clinical evaluation of Parkinson’s disease (PD) patients receiving integrated Chinese and Western medicine therapy. One hundred and twenty patients were enrolled and randomly allocated to a control group or treatment group. Patients in the two groups received placebo and Bushen Huoxue Granule (补肾活血颗粒
BHG)
respectively. Both groups received baseline levodopa and benserazide (Madopar). The effects of treatment were assessed monthly during the 9-month treatment. Means of evaluation included Unified PD Rating Scale (UPDRS) scores (II and III)
sleep scale score
10 m turn back test (getting up time
10 m×2 times
and turning time)
timing motor test (TMT)-left and TMT-right
which were treated as the dependent variables; and age
sex
duration of PD
Hoehn and Yahr (H-Y) stage and Madopar dosage of admitted PD patients were as the independent variables. Multiple linear regression was used to analyze these factors. H-Y stage significantly affected UPDRS II score
UPDRS III score
and getting up time (P<0.01). Madopar dosage and H-Y stage significantly affected the 10 m×2 times (P<0.05 or <0.01). Madopar dosage significantly affected the sleep scale score (P<0.05). There were also significant correlations between age and TMT-left or TMT-right (P<0.01)
and duration of PD and TMT-right (P<0.05). The six assessed means of clinical evaluation (including UPDRS II and UPDRS III scores
sleep scale score
getting up time
10 m×2 times
and turning time) are sensitive indexes in all PD patients. H-Y stage and Madopar dosage are the major factors influencing means of clinical assessment of PD treatment.
Abstract
To analyze the clinical evaluation of Parkinson’s disease (PD) patients receiving integrated Chinese and Western medicine therapy. One hundred and twenty patients were enrolled and randomly allocated to a control group or treatment group. Patients in the two groups received placebo and Bushen Huoxue Granule (补肾活血颗粒
BHG)
respectively. Both groups received baseline levodopa and benserazide (Madopar). The effects of treatment were assessed monthly during the 9-month treatment. Means of evaluation included Unified PD Rating Scale (UPDRS) scores (II and III)
sleep scale score
10 m turn back test (getting up time
10 m×2 times
and turning time)
timing motor test (TMT)-left and TMT-right
which were treated as the dependent variables; and age
sex
duration of PD
Hoehn and Yahr (H-Y) stage and Madopar dosage of admitted PD patients were as the independent variables. Multiple linear regression was used to analyze these factors. H-Y stage significantly affected UPDRS II score
UPDRS III score
and getting up time (P<0.01). Madopar dosage and H-Y stage significantly affected the 10 m×2 times (P<0.05 or <0.01). Madopar dosage significantly affected the sleep scale score (P<0.05). There were also significant correlations between age and TMT-left or TMT-right (P<0.01)
and duration of PD and TMT-right (P<0.05). The six assessed means of clinical evaluation (including UPDRS II and UPDRS III scores
sleep scale score
getting up time
10 m×2 times
and turning time) are sensitive indexes in all PD patients. H-Y stage and Madopar dosage are the major factors influencing means of clinical assessment of PD treatment.
关键词
Parkinson’s diseaseintegrated Chinese and Western medicine therapymeans of clinical evaluation
Keywords
Parkinson’s diseaseintegrated Chinese and Western medicine therapymeans of clinical evaluation
references
Sherer TB. Biomarkers for Parkinson’s disease. Sci Transl Med 2011;3:79ps14.
Nogawa S, Takahashi H, Hattori N. The development and validation of a new comprehensive self-completing questionnaire for symptoms in Parkinson’s disease (MASAC-PD 31). Clin Neurol 2011;51:321–329.
Yang MH, Li M, Dou YQ, Liu Y, Luo XD, Chen JZ, et al. Effects of Bushen Huoxue Granule on motor function in patients with Parkinson’s disease. J Chin Integr Med (Chin) 2010;8:231–237.
Li M, Yang MH, Yang B. Clinical research on cerebral neurotransmitters of Parkinson’s disease with strengening Kidney and activating circulation of traditional-Chinese medicine. Heart 2013;99(Suppl 3):A282.
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psych 1988;51:745–752.
Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001;57:1497–1499.
Müller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 2000;55:888–891.
Chen HB. Tanslations of the Unified Parkinson’s Disease Rating Scale (3.0,1987). Chin J Geriatic (Chin) 1999;18:61–62.
Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I, et al. Test-retest reliability of the unified Parkinson’s disease rating scale in patients with early Parkinson’s disease: results from a multicenter clinical trial. Mov Disord 2002,17:758–763.
Xin XL. The clinical study of repetitive transcranial magnetic stimulation on patients with Parkinson’s disease. Harbin: Heilongjiang University of Chinese Medicine, 2011.
Chaudhuri KR. Nocturnal symptom complex in PD and its management. Neurology 2003;61(Suppl 3):S17–S23.
Shang QH, Xu H, Lu XY, Wen C, Shi DZ, Chen KJ. A multicenter randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients. Chin J Integr Med 2011;17:669–674.
Li M, Yang MH, Liu Y. Effects of Chinese herb medicine Bushen Huoxue Granule on quality life of patients with Parkinson’s disease: a randomized, double-blinded and placebo-controlled trial. J Chin Integr Med (Chin) 2012;10:310–317.
Li M, Yang MH, Liu Y. Effects of “attenuation and synergia” for Bushen Huoxue Granules on Parkinson’s patients. J Chin Med Mater (Chin) 2012;35:503–506.
Porter B, Macfarlane R, Walker R. The frequency and nature of sleep disorders in a community-based population of patients with Parkinson’s disease. Eur J Neurol 2008;15:50–54.